Keyphrases
Improved Outcomes
100%
Mesenchymal Stem Cells
100%
COVID-19
100%
Mesenchymal Stem Cell Therapy
100%
Immunomodulatory Mechanisms
100%
Cell Infusion
25%
Neutrophil Extracellular Traps
25%
Immune System
12%
Placebo
12%
Adverse Events
12%
Phase II Clinical Trial
12%
Inflammatory Cytokines
12%
C-reactive Protein
12%
T Cells
12%
Placebo-controlled
12%
Immune Cells
12%
Hospital Stay
12%
Costimulatory Molecules
12%
Hematopoietic Stem Cells
12%
CD28
12%
Patient Outcomes
12%
Peripheral Blood
12%
Clinical Symptoms
12%
Venous Thrombosis
12%
Symptom Remission
12%
Severe Patients
12%
B Cell Subsets
12%
Single-cell RNA Sequencing Analysis
12%
SARS-CoV-2 Antibodies
12%
Chest CT Images
12%
Kindlin-3
12%
Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSCs)
12%
VNN2
12%
PTPRE
12%
CSF3R
12%
In Vivo Mice Study
12%
Immune Homeostasis
12%
Critical Patient
12%
Chemotaxis
12%
Neuroscience
Mesenchymal Stem Cell
100%
Coronavirinae
100%
Coronavirus
100%
In Vivo
18%
Placebo
18%
In Vitro
9%
T Cell
9%
Proinflammatory Cytokine
9%
SARS Coronavirus
9%
C-Reactive Protein
9%
RNA Sequence
9%
B Lymphocyte Subpopulation
9%
CD28
9%
Chemotaxis
9%
Antibodies
9%
Immunology and Microbiology
Mesenchymal Stem Cell
100%
COVID-19
100%
Neutrophil Extracellular Traps
18%
Immune System
9%
T Cell
9%
C-Reactive Protein
9%
CD28
9%
Immunocompetent Cell
9%
Homeostasis
9%
Chemotaxis
9%
RNA Sequence
9%
Proinflammatory Cytokine
9%
Severe Acute Respiratory Syndrome Coronavirus 2
9%
Immunity
9%
B Lymphocyte Subpopulation
9%
Umbilical Cord
9%
Antibodies
9%